Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial performance with a 10% revenue increase and a significant turnaround in net income. Additionally, the 25% growth in adjusted EBITDA and improved cash flow indicate operational efficiencies. Despite the lack of strategic updates, the financial results suggest a positive outlook. Given the company's market cap, these factors are likely to result in a moderate positive stock price movement of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Evolent Health reported revenue of $400 million for Q1 2026, representing a 10% increase year-over-year. The growth was attributed to the expansion of existing client relationships and the onboarding of new clients.
Adjusted EBITDA Adjusted EBITDA for Q1 2026 was $50 million, up 25% year-over-year. This improvement was driven by operational efficiencies and cost management initiatives.
Net Income Net income for Q1 2026 was $20 million, compared to a net loss of $5 million in Q1 2025. The turnaround was due to increased revenue and improved operational performance.
Operating Cash Flow Operating cash flow for Q1 2026 was $30 million, a 50% increase year-over-year. The increase was primarily due to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blair LLC
Caliendo UBS
Co Research
Director Mario
Division EDT
Division Kevin
Division Larsen
Division Lucas
Division Sahil
Division Tassan
Division Zachary
EDT reminder
Eduardo Ron
Haase Blair
Haggerty KeyBanc
Inc Research
Jared Haase
Kevin Caliendo
LLC Research
Larsen BTIG
Lucas Romanski
Mario Ramos
Officer Stansel
Piper Sandler
Research Division
Romanski TD
Sahil Veeramoney
Sandler Co
Seth Blackley
Stephens Inc
Tassan Piper
EVH Transcript
Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary highlights strong financial performance with a 10% revenue increase and a significant turnaround in net income. Additionally, the 25% growth in adjusted EBITDA and improved cash flow indicate operational efficiencies. Despite the lack of strategic updates, the financial results suggest a positive outlook. Given the company's market cap, these factors are likely to result in a moderate positive stock price movement of 2% to 8% over the next two weeks.
Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
Positive2-25
Evolent's earnings call reveals strong revenue growth projections driven by new contracts, including a significant partnership with Blue Cross, and enhanced margin protections. While there are concerns about membership declines in certain segments, the optimistic guidance, strategic deleveraging, and AI-driven efficiency improvements are positive indicators. The Q&A section further supports confidence in the company's conservative financial approach and potential growth in oncology. Despite some uncertainties, the overall sentiment suggests a positive stock price movement.
Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call presented strong financial performance with revenue and EBITDA at the upper range of guidance, driven by new launches and AI initiatives. The Q&A revealed confidence in future growth, with new contracts and stable oncology trends. Despite some uncertainty in membership impact on 2026 EBITDA, the overall sentiment remains positive with a focus on margin maturation and strategic partnerships. Considering the company's market cap of approximately $2.3 billion, the stock price is likely to react positively (2% to 8%) over the next two weeks.
EVH Slides
EVH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
